651 results on '"Kollmannsberger C"'
Search Results
2. Patient-reported psychosocial distress in adolescents and young adults with germ cell tumours
3. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
4. Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?
5. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
6. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
7. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
8. CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting
9. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
10. Novel treatment options for refractory Germ Cell Tumours: back to the bench!
11. Kanzerogenität
12. Teratogenität und Mutagenität
13. Gonadale Toxizität und Infertilität
14. Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC).
15. Pankreaskarzinom
16. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
17. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies
18. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy
19. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
20. Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)
21. Agenda science: turning nothing into something: a response to the editorial by Oldenburg et al. and its featured article by Vidal et al.
22. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
23. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer
24. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
25. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group
26. Behandlung von Patienten mit metastasierten Keimzelltumoren
27. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
28. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
29. Rolle der systemischen Therapie ± Radiotherapie beim resektablen Kardia-/Magenkarzinom
30. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer
31. The role of high-dose chemotherapy in relapsed germ cell tumors
32. Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience
33. Behandlung von Patienten mit cisplatinrefraktären Keimzelltumoren: Biologische und klinischeAspekte
34. Therapie von metastasierten Keimzelltumoren bei Patienten mit "Good-prognosis"- Kriterien
35. Ist die Adrenalektomie unverzichtbarer Bestandteil der Tumornephrektomie?: Ergebnis einer multivariaten statistischen Analyse
36. Adjuvante Radiochemotherapie (RTx/CTx) mit 5-FU/Folinsäure (FS)/Cisplatin (CDDP)/Paclitaxel (P) bei Patienten mit R0-Resektion bei High-risk-Magencarcinom (UICC-Stadien II-IV[M0])
37. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
38. Chemotherapie des metastasierten Blasenkarzinoms
39. Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer
40. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy
41. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
42. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
43. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
44. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
45. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer
46. Aktuelle Konzepte bei Hodentumoren: UICC-Symposium on Testicular Cancer, Tübingen, 19./20. März 1999
47. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés
48. 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
49. Patient-reported psychosocial distress in adolescents and young adults with germ cell tumours
50. Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.